Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 22;14(22):2093–2104. doi: 10.1111/1759-7714.14989

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Upregulation of AHNAK2 is correlated with poor prognosis in lung adenocarcinoma (LUAD) patients. (a) mRNA levels of AHNAK2 in LUAD tumor and normal tissues in TCGA (left) and GEO database (middle and right). (b) mRNA levels of AHNAK2 in LUAD tumor samples with different T stages. (c) Kaplan–Meier estimate of LUAD overall survival time based on AHNAK2 mRNA expression levels in all patients (left) and advanced patients (right). (d) Kaplan–Meier estimate of LUAD progression‐free survival time based on AHNAK2 mRNA expression levels. (e) Quantitative real‐time polymerase chain reaction (qRT‐PCR) of AHNAK2 was performed in adenocarcinoma tumor tissues and adjacent normal tissues.